Rethinking Dementia - A Unified Approach

🧠 The Brain Runs on Cholesterol But Not the Way You Think

The brain contains ~25% of the body’s total cholesterol, despite being only 2% of body weight.

But here’s the critical point:

👉 Brain cholesterol is made locally
👉 It cannot cross the blood–brain barrier

This cholesterol is essential for:

• Myelin formation (insulating nerve fibres)

• Synaptic signalling (memory and learning)

• Neurotransmitter receptor function

• Structural integrity of neurons

Without it, the brain simply cannot function properly.

⚠️ When Cholesterol Becomes Toxic - The Oxidative Trap

Cholesterol itself is not the enemy.

The problem begins when it is attacked by reactive oxygen species (ROS).

This creates toxic compounds called oxysterols, especially:

• 7-ketocholesterol (7KC)

• 7β-hydroxycholesterol (7βHC)

These drive a destructive cascade:

• 🔥 Excess ROS production (vicious cycle)

• 🧬 Mitochondrial damage

• 🧪 Neuroinflammation

• 💀 Neuronal death

This is one of the primary engines of neurodegeneration.

🔬 The Missing Piece - The Brain’s Mevalonate Pathway

This is where our work becomes truly groundbreaking.

Most people think the mevalonate pathway exists mainly to produce cholesterol.

But in the brain:

👉 Its most critical outputs are isoprenoids, not cholesterol.

Specifically:

• Farnesyl pyrophosphate (FPP)

• Geranylgeranyl pyrophosphate (GGPP)

These molecules enable protein prenylation, a process essential for:

• Synaptic vesicle release (memory signalling)

• Dendritic spine formation (learning)

• Axonal transport (cellular logistics)

• Mitochondrial function (energy)

Without GGPP:

Neurons lose their ability to communicate, adapt, and survive.

⚠️ A Critical Insight: It’s Not Just Deficiency - It’s Dysregulation

One of the most important findings:

• In ageing and statin use → GGPP can be depleted

• In Alzheimer’s → GGPP can be elevated but dysregulated

This creates two dangerous states:

1. Too Little (Depletion)

• Synaptic failure

• Impaired memory

• Neuronal death

2. Too Much (Dysregulated)

• Increased amyloid production

• Tau pathology

• Neuroinflammation

👉 The real goal is balance, not suppression

💊 The Statin Question - An Under-Recognised Risk

Our analysis highlights a major clinical concern:

Lipophilic statins (e.g. simvastatin, atorvastatin):

• Cross the blood–brain barrier

• Reduce GGPP more than cholesterol

• Impair synaptic function

In animal models:

• GGPP ↓ 33%

• FPP ↓ 52%

• Cholesterol ↓ only 22%

This disproportionate depletion directly affects:

• Memory

• Synaptic plasticity

• Neuronal surviva

🌿 A New Strategy - PREVENT + RESTORE

Our work identifies a dual-intervention model that addresses the entire cascade:

🛡️ 1. Annatto Tocotrienols (T3) - PREVENT

Key actions:

• 40–60× more potent antioxidant than alpha-tocopherol

• Prevents formation of toxic oxysterols (7KC, 7βHC)

• Modulates (not blocks) the mevalonate pathway

• Reduces neuroinflammation (NF-κB)

• Enhances synaptic signalling

👉 Stops damage at the source

🔧 2. Geranylgeraniol (GG) - RESTORE

Key actions:

• Direct precursor to GGPP

• Restores protein prenylation

• Reverses synaptic dysfunction

• Supports mitochondrial function via CoQ10

• Rescues statin-induced neuronal damage

👉 Rebuilds what the brain has lost

🔗 Why the Combination Matters

This is the breakthrough:

T3 protects the system. GG restores the system.

Together they:

• Prevent oxidative damage

• Restore synaptic communication

• Stabilise mitochondrial function

• Reduce inflammation

• Support myelin repair

No previous intervention has addressed all of these simultaneously.

🧠 The Three Stages of Cognitive Decline (A Practical Model)

Stage 1. Pre-MCI (Silent Phase)

• Early oxidative stress

• Declining GG and CoQ10

• Subtle synaptic inefficiency

Stage 2. Mild Cognitive Impairment (MCI)

• Impaired neurotransmission

• Memory lapses

• Rising toxic oxysterols

Stage 3. Dementia

• Amyloid and tau pathology

• Mitochondrial collapse

• Neuronal loss

👉 The intervention window is Stage 1–2
This is where prevention is still possible.

📊 Human Evidence Supporting This Model

Our research highlights key clinical findings:

• Higher tocotrienol levels → lower Alzheimer’s risk

• Tocotrienols slowed white matter lesion progression (2-year RCT)

• Improved memory and reduced inflammation in clinical trials

And critically:

Antioxidant depletion is already present in MCI, not just dementia.

🚨 Why This Matters Now

Dementia rates are rising globally.

But this research suggests:

👉 It is not inevitable
👉 It is biochemically driven
👉 It is potentially modifiable

And most importantly:

We now understand the system well enough to intervene intelligently.

✅ Key Takeaways

• Brain health depends on cholesterol AND isoprenoid balance

• Oxidative stress converts cholesterol into neurotoxic compounds

• GGPP is essential for memory, synapses, and neuron survival

• Ageing, statins, and disease disrupt this system

• A dual strategy of:

  • Tocotrienols (protect)

  • Geranylgeraniol (restore)
    offers a complete mechanistic solution

🔬 Final Word

This is more than a theory.

It is a fully integrated biological model of neurodegeneration, one that:

• Explains previous contradictions

• Identifies precise intervention points

• Opens the door to true prevention strategies

The upcoming BRAIN-GUARD Trial is the next critical step.

📩 Want to Stay Informed?

Subscribe to Natural Health Connect for ongoing updates on:

• Dementia prevention strategies

• Clinical trial developments

• Evidence-based nutritional interventions

References

Foundational Neuroscience - Mevalonate Pathway and Isoprenoids in the Brain

Kotti TJ, Ramirez DMO, Pfeiffer BE, Huber KM, Russell DW (2006). Brain cholesterol turnover required for geranylgeraniol production and learning in mice. Proc Natl Acad Sci USA, 103(10):3869–74.
https://www.pnas.org/doi/10.1073/pnas.0600316103

Eckert GP, Hooff GP, Strandjord DM, Igbavboa U, Volmer DA, Müller WE, Wood WG (2009). Regulation of the brain isoprenoids farnesyl- and geranylgeranylpyrophosphate is altered in male Alzheimer patients. Neurobiol Dis, 35(2):251–7.
https://pmc.ncbi.nlm.nih.gov/articles/PMC3778879/

Hooff GP, Wood WG, Müller WE, Eckert GP (2010). Isoprenoids, small GTPases and Alzheimer's disease. Biochim Biophys Acta, 1801(8):896–905.
https://pmc.ncbi.nlm.nih.gov/articles/PMC2886181/

Kotti TJ, McDonald DL, Stevenson DE, Kotti A, Sheroni NN, Ramirez DMO, Russell DW (2008). Biphasic requirement for geranylgeraniol in hippocampal long-term potentiation. Proc Natl Acad Sci USA, 105(32):11394–9.
https://www.pnas.org/doi/10.1073/pnas.0805556105

Hoof, G.P., Wood WG, Igbavboa U, Eckert GP, Müller WE (2012). Brain isoprenoids farnesyl pyrophosphate and geranylgeranyl pyrophosphate are increased in aged mice. Neurobiol Aging, 33(9):2031–2040.
https://pubmed.ncbi.nlm.nih.gov/22692983/

Schulz JG, Bösel J, Stoeckel M, Megow D, Dirnagl U, Endres M (2004). HMG-CoA reductase inhibition causes neurite loss by interfering with geranylgeranylpyrophosphate synthesis. J Neurochem, 89(1):24–32.
https://pubmed.ncbi.nlm.nih.gov/15030386/

Protein Prenylation and GTPase Signalling in Neurons

Afshordel S, Wood WG, Igbavboa U, Muller WE, Eckert GP (2014). Impaired geranylgeranyltransferase-I regulation reduces membrane-associated Rho protein levels in aged mouse brain. J Neurochem, 129(4):732–42.
https://pmc.ncbi.nlm.nih.gov/articles/PMC3999261/

Hooff GP, Wood WG, Müller WE, Eckert GP (2010). Isoprenoids, small GTPases and Alzheimer's disease (full review).
https://pmc.ncbi.nlm.nih.gov/articles/PMC2886181/

Cholesterol Oxidation and Oxysterols

Cutler RG, Kelly J, Storie K, Pedersen WA, Tammara A, Hatanpaa K, Troncoso JC, Mattson MP (2004). Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proc Natl Acad Sci USA, 101(7):2070–5.
https://pmc.ncbi.nlm.nih.gov/articles/PMC357053/

McComb M, Browne RW, Bhattacharya S, Bodziak ML, Jakimovski D, Weinstock-Guttman B, Kuhle J, Zivadinov R, Ramanathan M (2021). The cholesterol autoxidation products, 7-ketocholesterol and 7β-hydroxycholesterol are associated with serum neurofilaments in multiple sclerosis. Mult Scler Relat Disord, 50:102864.
https://pubmed.ncbi.nlm.nih.gov/33677412/

Oxysterol signalling in the central nervous system (2026, review). Front Mol Neurosci.
https://www.frontiersin.org/journals/molecular-neuroscience/articles/10.3389/fnmol.2026.1709065/full

GGPP Stimulation of γ-Secretase and Amyloid Pathology

Zhou Y, Suram A, Venugopal C, Prakasam A, Lin S, Su Y, Li B, Paul SM, Sambamurti K (2008). Geranylgeranyl pyrophosphate stimulates gamma-secretase to increase the generation of Aβ and APP-CTFγ. FASEB J, 22(1):47–54.
https://pmc.ncbi.nlm.nih.gov/articles/PMC2859886/

Statins and the Blood-Brain Barrier

Saheki A, Terasaki T, Tamai I, Tsuji A (1994). In vivo and in vitro blood-brain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors. Pharm Res, 11(2):305–11. Review: Statins and Neuroprotection (PMC2909025).
https://pubmed.ncbi.nlm.nih.gov/8165193/

Hydrophilic or Lipophilic Statins? Review (2021). Front Cardiovasc Med.
https://pmc.ncbi.nlm.nih.gov/articles/PMC8172607/

Statins and their influence on brain cholesterol (Sparks & Connor, 2011). Alzheimer's & Dementia, 7(4 Suppl).
https://www.sciencedirect.com/science/article/abs/pii/S1933287411006143

Simvastatin impairs hippocampal synaptic plasticity and cognitive function (2021). Mol Brain, 14(1):29.
https://pmc.ncbi.nlm.nih.gov/articles/PMC7905661/

Statin diversity: lipophilicity and BBB penetration (Tashko, 2025).
https://gertitashkomd.com/statin-diversity-a-deeper-dive-into-key-differences/

Geranylgeraniol - Neuronal Rescue, Mitochondria, NLRP3

Marcuzzi A, Piscianz E, Zweyer M, Bortul R, Loganes C, Girardelli M, Baj G, Monasta L, Celeghini C (2016). Geranylgeraniol and neurological impairment: involvement of apoptosis and mitochondrial morphology. Int J Mol Sci, 17(3):365.
https://pmc.ncbi.nlm.nih.gov/articles/PMC4813225/

Tricarico PM, Marcuzzi A, Piscianz E, Monasta L, Crovella S, Kleiner G (2013). Mevalonate kinase deficiency and neuroinflammation: balance between apoptosis and pyroptosis. Int J Mol Sci, 14(12):23274–88.
https://pmc.ncbi.nlm.nih.gov/articles/PMC3876043/

Geranylgeraniol Boosts Endogenous Synthesis of Coenzyme Q10 and Cell Essential Metabolites, Overcoming CoQ10 Supplementation Limitations https://townsendletter.com/geranylgeraniol-boosts-endogenous-synthesis-of-cq10-paul-et-al/

Tocotrienol Mechanisms

Parker RA, Pearce BC, Clark RW, Gordon DA, Wright JJ (1993). Tocotrienols regulate cholesterol production in mammalian cells by post-transcriptional suppression of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J Biol Chem, 268(15):11230–8.
https://pubmed.ncbi.nlm.nih.gov/8388388/

Pearce BC, Parker RA, Deason ME, Qureshi AA, Wright JJ (1992). Hypocholesterolemic activity of synthetic and natural tocotrienols. J Med Chem, 35(20):3595–606.
https://pubmed.ncbi.nlm.nih.gov/1433170/

Khanna S, Parinandi NL, Kotha SR, Roy S, Rink C, Bibus D, Sen CK (2010). Nanomolar vitamin E alpha-tocotrienol inhibits glutamate-induced activation of phospholipase A2 and causes neuroprotection. J Neurochem, 112(5):1249–60.
https://pmc.ncbi.nlm.nih.gov/articles/PMC2821814/

Sen CK, Khanna S, Roy S (2006). Tocotrienols: vitamin E beyond tocopherols. Life Sci, 78(18):2088–98.
https://pmc.ncbi.nlm.nih.gov/articles/PMC1790869/

Ang SY, Bhuvanendran S, Lee VLL, Tan JY, Radhakrishnan AK, Retinasamy T (2025). Modulation of NF-κB signaling pathway by tocotrienol in neurodegenerative diseases. Discov Ment Health, 5(1):160. [Monash University]
https://pmc.ncbi.nlm.nih.gov/articles/PMC12552194/

Kaileh M, Sen R (2010). Role of NF-kappaB in the anti-inflammatory effects of tocotrienols. J Am Coll Nutr, 29(3 Suppl):334S–339S.
https://pubmed.ncbi.nlm.nih.gov/20823493/

Naomi R, Shafie NH, Kaniappan P, Bahari H (2021). An interactive review on the role of tocotrienols in the neurodegenerative disorders. Front Nutr, 8:754086.
https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2021.754086/full

Novel Pathway for Tocotrienol in Neuroprotection (ExcelVite, 2021).
https://www.excelvite.com/novel-pathway-for-tocotrienol-in-neuroprotection/

Tocotrienol BBB Penetration

Kato Y, Uchiumi H, Usami R, Takatsu H, Aoki Y, Yanai S, Endo S, Fukui K (2021). Tocotrienols reach the brain and play roles in the attenuation of body weight gain and improvement of cognitive function in high-fat diet-treated mice. J Clin Biochem Nutr, 69(3):256–264.
https://pmc.ncbi.nlm.nih.gov/articles/PMC8611367/

Clinical Evidence - Tocotrienols and Brain Health

Gopalan Y, Shuaib IL, Magosso E, Ansari MA, Abu Bakar MR, Wong JW, Khan NAK, Liong WC, Sundram K, Ng BH, Karuthan C, Yuen KH (2014). Clinical investigation of the protective effects of palm vitamin E tocotrienols on brain white matter. Stroke, 45(5):1422–8.
https://www.ahajournals.org/doi/10.1161/strokeaha.113.004449

Lopresti AL, Smith SJ, Ding L, Li Y, Zhang P (2025). An examination into the effects of tocotrienols (TheraPrimE® rice) on cognitive abilities and sleep in healthy adults: a randomised, double-blind, placebo-controlled trial. Front Nutr, 12:1621516.
https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2025.1621516/full

Mangialasche F, Kivipelto M, Mecocci P, Rizzuto D, Palmer K, Winblad B, Fratiglioni L (2010). High plasma levels of vitamin E forms and reduced Alzheimer's disease risk in advanced age. J Alzheimers Dis, 20(4):1029–37.
https://pubmed.ncbi.nlm.nih.gov/20413888/

Mangialasche F, Solomon A, Kåreholt I, Hooshmand B, Cecchetti R, Fratiglioni L, Soininen H, Laatikainen T, Mecocci P, Kivipelto M (2013). Serum levels of vitamin E forms and risk of cognitive impairment in a Finnish cohort of older adults. Exp Gerontol, 48(12):1428–35.
https://pubmed.ncbi.nlm.nih.gov/24113154/

Boccardi V, Baroni M, Mangialasche F, Mecocci P (2016). Vitamin E family: role in the pathogenesis and treatment of Alzheimer's disease. Alzheimers Dement (NY), 2(3):182–191.
https://pmc.ncbi.nlm.nih.gov/articles/PMC5651353/

This white paper was prepared for Natural Health Connect and the BRAIN-GUARD Pilot Trial programme. All referenced findings are from peer-reviewed published research. This document is intended for scientific and regulatory review purposes and does not constitute medical advice.

Research Report NHC-R-003-03 | © 2026 Natural Health Connect. All rights reserved.